<html><head></head><body><h1>Ipratropium (Systemic, Oral Inhalation)</h1><p class="drug-subtitle"><b>Class:</b> Antimuscarinics/Antispasmodics<br/>
<b>VA Class:</b> RE105<br/>
<b>Molecular Formula:</b> C<sub>20</sub>H<sub>30</sub>BrNO<sub>3</sub>•H<sub>2</sub>O<br/>
<b>CAS Number:</b> 66985-17- 9<br/>
<b>Brands:</b> Atrovent</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Bronchodilator; a nonselective, competitive antagonist at muscarinic receptors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;224&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;232&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Ipratropium (Systemic, Oral Inhalation)</h2><h3>Bronchospasm in COPD</h3><p>Long-term treatment of reversible bronchospasm associated with COPD,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;58&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;76&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;118&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;122&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;123&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;127&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;130&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;244&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;245&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;253&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;254&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;255&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;258&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;263&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;267&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;278&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;285&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;292&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;293&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;294&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; including chronic bronchitis&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;36&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;55&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;61&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;76&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;90&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;125&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;131&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and emphysema.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;90&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;91&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;125&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;343&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;344&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;345&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;347&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Fixed combination with albuterol sulfate is used for the symptomatic management of bronchospasm associated with COPD in patients who continue to have evidence of bronchospasm despite the regular use of an orally inhaled bronchodilator and who require a second bronchodilator.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;347&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Bronchospasm in Asthma</h3><p>Has been used for symptomatic treatment of acute or chronic bronchial asthma†;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;36&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;55&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;56&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;76&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;91&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;92&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;125&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;129&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;161&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;162&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;181&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;211&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;268&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;331&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;336&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;337&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; β<sub>2</sub>-adrenergic agonist bronchodilators generally preferred <i>initially</i> for relief of bronchospasm in asthmatic patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;161&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;268&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;303&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;331&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;337&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May be useful as alternative therapy in adults experiencing adverse effects (e.g., tachycardia, arrhythmia, tremor) with a β-adrenergic agonist†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;331&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;336&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;337&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some clinicians consider ipratropium as <i>adjunctive</i> therapy in patients with moderate or severe exacerbations (peak expiratory flow rate ≤80% of predicted) of asthma† who fail to respond adequately to β-adrenergic agonists and corticosteroids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;331&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;337&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May be useful for prevention or reversal of bronchospasm induced by β-adrenergic blocking agents† (e.g., propranolol) in asthmatic patients; β-adrenergic bronchodilators generally ineffective for this indication in such patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;194&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;268&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Ipratropium (Systemic, Oral Inhalation) Dosage and Administration</h2><h3>Administration</h3><p>Administer by oral inhalation using an oral aerosol inhaler&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or via nebulization.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Aerosol delivers ≥200 metered sprays per canister.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patient should be instructed to clear excessive sputum from chest before inhalation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Shake well immediately prior to use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Actuate aerosol inhaler 3 times prior to the initial use or if it has not been used for &gt;24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not use mouthpiece for other aerosol drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Exhale slowly and completely and place the mouthpiece of the inhaler well into the mouth with the lips closed around it.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;348&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; To avoid contact of the drug with the eyes and subsequent adverse effects, close eyes during inhalation of aerosol.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;348&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Inhale slowly and deeply through the mouth while actuating the inhaler.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Hold the breath for 10 seconds, withdraw the mouthpiece, and exhale slowly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Allow ≥15 seconds to elapse between subsequent inhalations from the aerosol inhaler.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;348&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Wash the mouthpiece in hot running water as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;348&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If soap is used, rinse mouthpiece thoroughly with plain water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;348&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Aerosol delivers ≥200 metered sprays per canister.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Shake well immediately prior to use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Actuate 3 times prior to the initial use or if it has not been used for &gt;24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not use actuator provided for other aerosol drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; To avoid contact of the drug with the eyes and subsequent adverse effects, close eyes during inhalation of aerosol.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Exhale deeply and place mouthpiece of the inhaler into the mouth.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Inhale slowly and deeply through the mouth while actuating the inhaler.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Hold the breath for 10 seconds, withdraw the mouthpiece, and exhale slowly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Allow approximately 2 minutes to elapse and repeat the procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Rinse the mouthpiece in hot water as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If soap is used, rinse the mouthpiece thoroughly with plain water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; When dry, replace the cap on the mouthpiece when the inhaler is not in use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;346&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Empty entire contents of the single-use vial of solution into the nebulizer reservoir and attach reservoir to the mouthpiece or face mask and to the compressor according to the manufacturer’s instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;350&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use care when a face mask is used to avoid leakage since transient blurred vision and other adverse effects may result if the drug enters the eyes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;250&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;275&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;350&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Ocular Effects under Cautions.) Use of a mouthpiece may avoid inadvertent entry of drug into the eye.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Place the mouthpiece of the nebulizer in the mouth or put on the nebulizer face mask.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Breathe as calmly, deeply, and evenly as possible until the nebulizer stops producing mist.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Duration of treatment usually is about 5–15 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Empty entire contents of the single-use vial of solution into the nebulizer reservoir and attach reservoir to the mouthpiece or face mask and to the compressor according to the manufacturer’s instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Place the mouthpiece of the nebulizer in the mouth or put on the nebulizer face mask.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Breathe as calmly, deeply, and evenly as possible until the nebulizer stops producing mist.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Duration of treatment usually is about 5–15 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Clean the nebulizer after use according to the manufacturer’s instructions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Available as ipratropium bromide.</p><p>Dosage of oral inhalation aerosol expressed in terms of the monohydrate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage of inhalation solution for nebulization expressed in terms of anhydrous drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;330&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Using in vitro testing at an average flow rate of 3.6 L per minute for an average of ≤15 minutes, the Pari-LC Plus<sup></sup> nebulizer delivered at the mouthpiece approximately 46 or 42% of the original dosage of albuterol or ipratropium bromide, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;327&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients ≥12 years of age: 36 mcg (2 inhalations) 4 times daily via a metered-dose aerosol, given alone or in fixed combination with albuterol (90 mcg via the mouthpiece).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Additional inhalations should not exceed 216 mcg (12 inhalations) of ipratropium bromide in 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients ≥12 years of age: 500 mcg (contents of 1 unit-dose vial) 3 or 4 times daily (i.e., every 6–8 hours) via a nebulizer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 36 mcg (2 inhalations) 4 times daily via a metered-dose aerosol, given alone or in fixed combination with albuterol (90 mcg from the mouthpiece).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Additional inhalations should not exceed 216 mcg (12 inhalations) in 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initially, 500 mcg 3 or 4 times daily (i.e., every 6–8 hours) via a nebulizer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; With ipratropium bromide in fixed combination with albuterol sulfate (DuoNeb<sup></sup>), 500 mcg 4 times daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;327&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Additional inhalations should not exceed 6 inhalations daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;327&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Maximum 216 mcg (12 inhalations via a metered-dose inhaler) in 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum 12 inhalations via metered-dose inhaler in 24 hours with the fixed combination of ipratropium bromide and albuterol sulfate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>500 mcg 3–4 times daily via a nebulizer in patients ≥12 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum 216 mcg (12 inhalations via a metered-dose inhaler) in 24 hours;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; frequency of administration should not exceed 4 times daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;267&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;323&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maximum 12 inhalations via metered-dose inhaler in 24 hours with the fixed combination of ipratropium bromide and albuterol sulfate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>500 mcg 3–4 times daily via a nebulizer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Dosage adjustments based solely on age are not necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Ipratropium (Systemic, Oral Inhalation)</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to the drug or any other component of the formulation, or to atropine or its derivatives.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Known hypersensitivity to soya lecithin or related food products, including soybeans and peanuts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;277&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to the drug or any other component of the formulation, or to atropine or its derivatives.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Known hypersensitivity to soya lecithin or related food products, including soybeans and peanuts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;277&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Delayed onset of action; <i>not</i> indicated for <i>initial</i> treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Generally should <i>not</i> be used <i>alone</i> for the management of acute bronchospasm, when a rapid response is required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Immediate hypersensitivity reactions, including rash, angioedema of the tongue, lips, and face, urticaria, bronchospasm, oropharyngeal edema, and anaphylactic reaction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;213&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;277&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;285&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible paradoxical bronchospasm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;196&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;270&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;271&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;272&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;273&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Contact a clinician immediately if a previously effective dosage regimen fails to provide the usual relief (e.g., need to increase the dose or frequency of administration of the drug).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not increase the dose or frequency of inhalation without consultation with a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible temporary blurred vision,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; mydriasis,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;250&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;275&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; ocular pain,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; conjunctival or corneal congestion associated with visual halos or colored images,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or precipitation or worsening of angle-closure glaucoma&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;173&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;337&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; following inadvertent contact of ipratropium with the eyes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;349&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Minimize ocular exposure by using a mouthpiece rather than a face mask during administration via a nebulizer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; During oral inhalation of aerosol, close eyes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Inhalation aerosol should not be administered using the open-mouth technique in these patients with angle-closure glaucoma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;173&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution in patients with angle-closure glaucoma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible urinary retention/difficulty,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;251&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;252&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; urinary tract infection,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or dysuria.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with bladder neck obstruction or prostatic hypertrophy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible adverse cardiovascular effects (e.g., tachycardia, palpitations, aggravated hypotension or hypertension).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.</p><p>Category B.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of oral inhalation not established in children &lt;12 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Bronchitis, upper respiratory tract infection,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; cough,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;87&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;285&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and dryness of the mouth,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;60&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;90&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;127&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; throat,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;75&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;90&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or tongue&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;87&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; with ipratropium aerosol. Adverse effects resulting in discontinuance of nebulized ipratropium most frequently include bronchitis, dyspnea, and bronchospasm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Ipratropium (Systemic, Oral Inhalation)</h2><p>Limited systemic absorption following oral inhalation; interactions with systemically administered drugs unlikely.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;191&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Antimuscarinic agents</p><p>Potential pharmacodynamic interaction (additive effects)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Caution advised with concomitant administration&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Methylxanthine derivatives</p><p>No adverse drug interactions reported&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;132&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;157&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;158&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;187&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;220&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;305&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>β-Adrenergic agonists</p><p>Potential pharmacodynamic interaction (additive effects)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;133&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;147&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;152&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;155&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;246&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;248&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;260&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;278&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;279&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;285&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;287&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;288&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;289&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If concomitant therapy is required, consider cautious use of cardioselective β-adrenergic blocking agents&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;132&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;139&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;146&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;154&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;181&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;216&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Corticosteroids</p><p>No adverse drug interactions reported&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;91&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;132&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;154&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;160&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;329&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cromolyn sodium</p><p>No adverse drug interactions reported&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;132&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Ipratropium (Systemic, Oral Inhalation) Pharmacokinetics</h2><h3>Absorption</h3><p>Only minimally absorbed into systemic circulation following oral inhalation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;106&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Bronchodilation evident within 15 minutes following oral aerosol inhalation&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and within 15–30 minutes following oral inhalation via nebulization.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;86&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Bronchodilation generally persists for 3–4 hours following oral aerosol inhalation&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;230&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and for 4–5 hours following nebulization.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;86&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Does not readily penetrate the CNS.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; It is not known whether the drug crosses the placenta or is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>0–9%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Metabolized partially to at least 8 metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;106&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Excreted principally in feces as unchanged drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;109&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Following oral inhalation of radiolabeled ipratropium bromide, about 69 and 3.2% of the dose was excreted in feces and urine, respectively, within 6–7 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;106&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;109&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Undergoes some biliary elimination.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>1.6 hours (t<sub>½β</sub> with IV administration).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;190&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;229&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>15–30 °C (metered-dose inhalers or inhalation solution of ipratropium bromide).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>2–25°C (oral inhalation solution of ipratropium bromide in fixed combination with albuterol sulfate); protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;327&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;328&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>A nonselective competitive antagonist at muscarinic receptors present in airways and other organs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;224&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;232&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Relaxes smooth muscles of bronchi and bronchioles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Blocks acetylcholine-induced stimulation of guanyl cyclase and reduces formation of cyclic guanosine monophosphate (cGMP), a mediator of bronchoconstriction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Exhibits greater antimuscarinic activity on bronchial smooth muscle than on secretory (e.g., salivary, gastric) glands.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Tolerance to bronchodilating effect does not develop with prolonged use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;90&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;91&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;92&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;118&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;168&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;278&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>A nonselective competitive antagonist at muscarinic receptors present in airways and other organs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;224&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;232&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Relaxes smooth muscles of bronchi and bronchioles.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Blocks acetylcholine-induced stimulation of guanyl cyclase and reduces formation of cyclic guanosine monophosphate (cGMP), a mediator of bronchoconstriction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Exhibits greater antimuscarinic activity on bronchial smooth muscle than on secretory (e.g., salivary, gastric) glands.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;34&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tolerance to bronchodilating effect does not develop with prolonged use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;90&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;91&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;92&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;118&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;168&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;278&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of providing patients with a copy of the manufacturer’s patient information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of using proper administration technique.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients that oral inhalation is not intended for occasional use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use consistently throughout the course of therapy for maximum effectiveness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of contacting a clinician if symptoms of COPD are not relieved by usually effective doses or if they worsen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not increase the dosage or frequency of administration without consultation with a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients to close their eyes during oral inhalation of aerosol&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; to avoid inadvertent contact of the drug with the eyes and subsequent adverse effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of contacting a clinician immediately if ocular symptoms develop.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients that blurring of vision, precipitation or aggravation of narrow angle glaucoma, mydriasis, visual halos, colored images in association with conjunctival or corneal congestion, or eye pain or discomfort may result from contact of the inhalation solution with the eyes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians if ocular adverse effects develop.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information. (See Cautions.)</p>
</li>
</ul><p>Importance of providing patients with a copy of the manufacturer’s patient information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of using proper administration technique.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients that oral inhalation is not intended for occasional use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use consistently throughout the course of therapy for maximum effectiveness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of contacting a clinician if symptoms of COPD are not relieved by usually effective doses or if they worsen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not increase the dosage or frequency of administration without consultation with a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients to close their eyes during oral inhalation of aerosol&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; to avoid inadvertent contact of the drug with the eyes and subsequent adverse effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of contacting a clinician immediately if ocular symptoms develop.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients that blurring of vision, precipitation or aggravation of narrow angle glaucoma, mydriasis, visual halos, colored images in association with conjunctival or corneal congestion, or eye pain or discomfort may result from contact of the inhalation solution with the eyes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians if ocular adverse effects develop.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information. (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral Inhalation</p><p>Aerosol</p><p>18 mcg/metered spray</p><p>Atrovent<sup></sup> (with chlorofluorohydrocarbon propellants and soya lecithin)</p><p>Boehringer Ingelheim</p><p>Solution, for nebulization</p><p>0.02%*</p><p>Atrovent<sup></sup> (preservative-free)</p><p>Boehringer Ingelheim</p><p>Ipratropium Bromide Inhalation Solution (preservative-free)</p><p>Alpharma, Dey, Holopack, Nephron, Novex, Roxane, RxElite, Teva, Warrick</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral Inhalation Only</p><p>Aerosol</p><p>18 mcg with Albuterol Sulfate 90 mcg (of albuterol) per metered spray</p><p>Combivent<sup></sup> (with chlorofluorohydrocarbon propellants and soya lecithin)</p><p>Boehringer Ingelheim</p><p>Solution, for nebulization</p><p>0.5 mg with Albuterol Sulfate 2.5 mg (of albuterol) per 3 mL</p><p>DuoNeb<sup></sup></p><p>Dey</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions July 1, 2006. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>1. Boehringer Ingelheim. Atrovent<sup></sup> (ipratropium bromide) inhalation aerosol prescribing information. Ridgefield, CT; 2002 Mar 27.</p><p>2. Boehringer Ingelheim. Atrovent<sup></sup> product monograph. Ridgefield, CT; 1987 Feb.</p><p>3. Boehringer Ingelheim. Atrovent<sup></sup> product information form for American Hospital Formulary Service. Ridgefield, CT; 1987 Feb.</p><p>4. Boehringer Ingelheim. Atrovent<sup></sup> (ipratropium bromide) 0.02% inhalation solution prescribing information. Ridgefield, CT; 1998 Oct.</p><p>5. Budavari S, O’Neil MJ, Smith A et al, eds. The Merck index. 11th ed. Rahway, NJ: Merck &amp; Co., Inc; 1989:4956-7.</p><p>6. Pakes GE, Brogden RN, Heel RC et al. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. <i>Drugs</i>. 1980; 20:237-66. http://www.ncbi.nlm.nih.gov/pubmed/6448137?dopt=AbstractPlus</p><p>7. Bauer R, Banholzer R, Grieben C et al. Ipratropium bromide. In: Goldberg ME, ed. Pharmacological and biochemical properties of drug substances. 1979; 2:489-515.</p><p>8. Deckers W. The chemistry of new derivatives of tropane alkaloids and the pharmacokinetics of a new quaternary compound. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):76-81. http://www.ncbi.nlm.nih.gov/pubmed/134360?dopt=AbstractPlus</p><p>9. Winthrop-Breon. How to correctly use your Tornalate<sup></sup> (bitolterol meyslate) metered dose inhaler. New York; 1985 Jan.</p><p>10. Boehringer Ingelheim. Questions and answers about Atrovent<sup></sup> (ipratropium bromide) inhalation aerosol 18 µg per puff. Ridgefield, CT; 1987 Mar.</p><p>11. Brown JH. Atropine, scopolamine, and related antimuscarinic drugs. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:159-60.</p><p>12. Englehardt A. Pharmacology and toxicology of Atrovent. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):110-5.</p><p>13. Bauer R, Kuhn FJ, Stockhaus K et al. Allgemeine Pharmakologie und seckretionshemmende Wirkung von (8r)-3α-Hydroxy-8-isopropyl- 1αH,5αH-tropaniumbromid-()tropat (Ipratropiumbromid). (German; with English abstract.) <i>Arzneim-Forsch</i>. 1976; 26:974-80.</p><p>14. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. <i>Am Rev Respir Dis</i>. 1984; 129:856-70. http://www.ncbi.nlm.nih.gov/pubmed/6372560?dopt=AbstractPlus</p><p>15. Genentech, Inc. Patient information booklet: your guide to Pulmozyme<sup></sup> (dornase alfa) therapy for cystic fibrosis (CF). South San Francisco, CA; 1994.</p><p>16. Bleichert A. Zur Frage der Nebenwirkungen anticholinerger Drogen in Abhängigkeit von der Applikationsart: inhalation versus intravenöse Injektion von Ipratropiumbromid. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1976; 26:1010-3.</p><p>17. Otto P. Untersuchungen über die Hemmung der Magensaftsekretion beim Menschen durch den Atropinabkömmling N-Isopropyl-nortropintropasäureester-brommethylat. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1973; 23:1334-6.</p><p>18. Bauer R, Püschmann S, Wick H et al. Wirkung von (8r)-3α-Hydroxy-8-isopropyl-1αH,5αH-tropaniumbromid-()- tropat (Ipratropiumbromid) auf Spasmen des Tracheobronchialbaumes und die Bronchialsekretion, die Speichelsekretion, EKG und Herzfrequenz. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1976; 26:981-5.</p><p>19. Morris HG. Review of ipratropium bromide in induced bronchospasm in patients with asthma. <i>Am J Med</i>. 1986; 81(Suppl 5A):36-44. http://www.ncbi.nlm.nih.gov/pubmed/2947459?dopt=AbstractPlus</p><p>20. Cockcroft DW, Ruffin RE, Hargreave FE. Effect of Sch1000 in allergen-induced asthma. <i>Clin Allergy</i>. 1978; 8:361-72. http://www.ncbi.nlm.nih.gov/pubmed/152170?dopt=AbstractPlus</p><p>21. Bandouvakis J, Cartier A, Roberts R et al. The effect of ipratropium and fenoterol on methacholine- and histamine-induced bronchoconstriction. <i>Br J Dis Chest</i>. 1981; 75:295-305. http://www.ncbi.nlm.nih.gov/pubmed/6457620?dopt=AbstractPlus</p><p>22. Woenne R, Kattan M, Orange RP et al. Bronchial hyperreactivity to histamine and methacholine in asthmatic children after inhalation of SCH 1000 and chlorpheniramine maleate. <i>J Allergy Clin Immunol</i>. 1978; 62:119-24. http://www.ncbi.nlm.nih.gov/pubmed/149804?dopt=AbstractPlus</p><p>23. Giulekas D, Tsakalos N, Georgopoulos D et al. Effect of ipratropium bromide on repeated methacholine challenges. <i>Ann Allergy</i>. 1985; 55:835-9. http://www.ncbi.nlm.nih.gov/pubmed/2934009?dopt=AbstractPlus</p><p>24. Larsson K. Ipratropium bromide: bronchodilator action and effect on methacholine-induced bronchoconstriction. <i>J Asthma</i>. 1987; 24:29-35. http://www.ncbi.nlm.nih.gov/pubmed/2975285?dopt=AbstractPlus</p><p>25. de Vries K. The protective effect of inhaled Sch 1000 MDI on bronchoconstriction induced by serotonin, histamine, acetylcholine and propranolol. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):106.</p><p>26. Nolte D. The action of Sch 1000 MDI on experimental bronchoconstriction induced by various types of nonspecific and pharmacodynamic irritants in young asthmatics. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):103. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495705&amp;blobtype=pdf</p><p>27. Beumer HM. The antagonistic effect of several doses of inhaled Sch 1000 administered by metered dose inhaler (MDI) on a Bird respirator on acetylcholine-induced bronchospasm. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):101-2.</p><p>28. Harnett J, Spector SL. Blocking effect of SCH 1000, isoproterenol, and the combination on methacholine and histamine inhalations. <i>J Allergy Clin Immunol</i>. 1976; 57:261.</p><p>29. Kersten W. The role of Sch 1000 MDI in preventing a rise in total airways resistance (R<sub>t</sub>) induced by inhaled allergen in patients with atopic asthma. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):103. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495705&amp;blobtype=pdf</p><p>30. Killian D, Mellon A, Hargreave FE. Protective effect of drugs on histamine-induced asthma. <i>J Allergy Clin Immunol</i>. 1976; 57:263.</p><p>31. Germouty J. The possible antagonism between Sch 1000 MDI and beta-blocking agents. <i>Postgrad Med</i>. 1975; 51(Suppl 7):103.</p><p>32. Chan-Yeung M. The effect of Sch 1000 and disodium cromoglycate on exercise-induced asthma. <i>Chest</i>. 1977; 71:320-3. http://www.ncbi.nlm.nih.gov/pubmed/138577?dopt=AbstractPlus</p><p>33. Tullett WM, Patel KR, Berkin KE et al. Effect of lignocaine, sodium cromoglycate, and ipratropium bromide in exercise-induced asthma. <i>Thorax</i>. 1982; 37:737-40. http://www.ncbi.nlm.nih.gov/pubmed/6218645?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=459417&amp;blobtype=pdf</p><p>34. Hartley JPR, Davies BH. Cholinergic blockade in the prevention of exercise-induced asthma. <i>Thorax</i>. 1980; 35:680-5. http://www.ncbi.nlm.nih.gov/pubmed/6449753?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=471361&amp;blobtype=pdf</p><p>35. Borut TC, Tashkin DP, Fischer TJ et al. Comparison of aerosolized atropine sulfate and Sch 1000 on exercise-induced bronchospasm in children. <i>J Allergy Clin Immunol</i>. 1977; 60:127-33. http://www.ncbi.nlm.nih.gov/pubmed/141471?dopt=AbstractPlus</p><p>36. Poppius H, Salorinne Y, Viljanen AA. Inhalation of a new anticholinergic drug, Sch 1000, in asthma and chronic bronchitis: effect on airway resistance, thoracic gas volume, blood gases and exercise-induced asthma. <i>Bull Physiopathol Resp</i>. 1972; 8:643-52.</p><p>37. Poppius H, Salorinne Y, Viljanen AA. The role of Sch 1000 MDI in preventing exercise-induced asthma. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):105. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495711&amp;blobtype=pdf</p><p>38. Weinberg EG. Experience with Sch 1000 MDI in the treatment of exercise-induced asthma in children. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):128.</p><p>39. Thomson NC, Patel KR, Kerr JW. Sodium cromoglycate and ipratropium bromide in exercise-induced asthma. <i>Thorax</i>. 1978; 33:694-9. http://www.ncbi.nlm.nih.gov/pubmed/154747?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=470965&amp;blobtype=pdf</p><p>40. Sanguinetti CM, De Luca S, Gasparini S et al. Evaluation of Duovent in the prevention of exercise-induced asthma. <i>Respiration</i>. 1986; 50(Suppl 2):181-5. http://www.ncbi.nlm.nih.gov/pubmed/2951802?dopt=AbstractPlus</p><p>41. Dry J, Pradalier A, Leynadier F et al. Recherche d’une prévention de la bronchoconstriction induite par une épreuve d’efforts chez l’asthmatique par un atropinique de synthèse: le Sch 1000. (French; with English abstract.) <i>Thérapie</i>. 1977; 32:181-8.</p><p>42. Anderson S, Seale JP, Ferris L et al. An evaluation of pharmacotherapy for exercise-induced asthma. <i>J Allergy Immunol</i>. 1979; 64:612-24.</p><p>43. Poppius H, Sovijärvi ARA, Tammilehto L. Controlled study on the preventing effect of inhaled ipratropium powder on asthma induced by breathing cold air during exercise. <i>Respiration</i>. 1984; 46(Suppl):45-6. http://www.ncbi.nlm.nih.gov/pubmed/6436932?dopt=AbstractPlus</p><p>44. Wolkove N, Kreisman H, Frank H et al. The effect of ipratropium on exercise-induced bronchoconstriction. <i>Ann Allergy</i>. 1981; 47:311-5. http://www.ncbi.nlm.nih.gov/pubmed/6459045?dopt=AbstractPlus</p><p>45. Scano G, Stendardi L, Gigliotti G et al. Comparative effects of SCH 1000 and fenoterol after histamine-induced bronchoconstricition in asymptomatic asthmatics. <i>Intl J Clin Pharmacol Ther Toxicol</i>. 1984; 22:81-5.</p><p>46. Dorward AJ, Patel KR. A comparison of ketotifen with clemastine, ipratropium bromide and sodium cromoglycate in exercise-induced asthma. <i>Clin Allergy</i>. 1982; 12:355-61. http://www.ncbi.nlm.nih.gov/pubmed/6214337?dopt=AbstractPlus</p><p>47. Yeung R, Nolan GM, Levison H. Comparison of the effects of inhaled SCH 1000 and fenoterol on exercise-induced bronchospasm in children. <i>Pediatrics</i>. 1980; 66:109-14. http://www.ncbi.nlm.nih.gov/pubmed/6447269?dopt=AbstractPlus</p><p>48. Nair N, Townley RG, Watt G et al. Protection by ipratropium bromide and metaproterenol against methacholine and histamine bronchoconstriction. <i>Clin Allergy</i>. 1984; 24:11-9.</p><p>49. Clarke PS, Jarrett RG, Hall GJL. The protective effect of ipratropium bromide aerosol against bronchospasm induced by hyperventilation and the inhalation of allergen, methacholine and histamine. <i>Ann Allergy</i>. 1982; 48:180-3. http://www.ncbi.nlm.nih.gov/pubmed/6461281?dopt=AbstractPlus</p><p>50. Cockcroft DW, Killian DN, Mellon JJA et al. Protective effect of drugs on histamine-induced asthma. <i>Thorax</i>. 1977; 32:429-37. http://www.ncbi.nlm.nih.gov/pubmed/145036?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=470644&amp;blobtype=pdf</p><p>51. Gayrard P, Orehek J, Charpin J et al. The prevention of the bronchoconstrictor effects of deep inspiration or of cigarette smoking in asthmatic patients by Sch 1000. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):102-3.</p><p>52. Widdicombe JG. Reflex control of tracheobronchial smooth muscle in experimental and human asthma. In: Lichtenstein LM, Austen KF, eds. Asthma: physiology, immunopharmacology, and treatment. New York: Academic Press; 1977:225-31.</p><p>53. Islam MS, Ulmer WT. Influence of the inhalative aerosol Atrovent<sup></sup> on airway resistance and intrathoracic gas volume in healthy volunteers of different ages. <i>Respiration</i>. 1984; 45:225-31. http://www.ncbi.nlm.nih.gov/pubmed/6235557?dopt=AbstractPlus</p><p>54. Douglas NJ, Sudlow MF, Flenley DC. Effect of an inhaled atropinelike agent on normal airway function. <i>J Appl Physiol</i>. 1979; 46:256-62. http://www.ncbi.nlm.nih.gov/pubmed/154492?dopt=AbstractPlus</p><p>55. Thiessen B, Pedersen OF. A double blind cross-over study of maximal expiratory flows and arterial blood gas tensions in normals, asthmatics and bronchitis after salbutamol and ipratropin. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):170-7.</p><p>56. Partridge MR, Saunders KB. Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma. <i>Thorax</i>. 1981; 36:530-3. http://www.ncbi.nlm.nih.gov/pubmed/6458921?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1020436&amp;blobtype=pdf</p><p>57. Hensley MJ, O’Cain CF, McFadden ER Jr et al. Distribution of bronchodilatation in normal subjects: beta agonist versus atropine. <i>J Appl Physiol</i>. 1978; 45:778-82. http://www.ncbi.nlm.nih.gov/pubmed/730574?dopt=AbstractPlus</p><p>58. Günther W, Kamburoff PL. The bronchodilator effect of a new anticholinergic drug, Sch 1000. <i>Curr Med Res Opin</i>. 1974; 2:281-7. http://www.ncbi.nlm.nih.gov/pubmed/4416109?dopt=AbstractPlus</p><p>59. Böhning W, Fabel H. Comparison of the onset of action of Sch 1000 and orciprenaline given by metered dose inhaler (MDI). <i>Postgrad Med J</i>. 1975; 51(Suppl 7):95.</p><p>60. Gross HJ. Dose-response study of the effect of Sch 1000 MDI on forced vital capacity (FVC), FEV<sub>10</sub>, maximal midexpiratory flow (MMEF) and heart rate, ECG and blood pressure. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):95-6.</p><p>61. Heller KF. Changes in total airways resistance (R<sub>t</sub>) and thoracic gas volume (TGV) following Sch 1000 MDI or placebo. Multiple dose study over 12 hours. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):96. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495706&amp;blobtype=pdf</p><p>62. Irsigler G. Flow volume curves and changes in FEV<sub>10</sub> forced vital capacity (FVC), mid and slow vital capacity (Mid VC and SVC) in patients with bronchial asthma or chronic bronchitis and emphysema following increasing dosages of Sch 1000 MDI. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):96. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495706&amp;blobtype=pdf</p><p>63. Loddenkemper R. Dose- and time-response of Sch 1000 MDI on total (R<sub>t</sub>) and expiratory (R<sub>t</sub>) airways resistance in patients with chronic bronchitis and emphysema. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):97.</p><p>64. Bell JA, Bluestein BM, Danta I et al. Effect of inhaled ipratropium bromide on tracheal mucociliary transport in bronchial asthma. <i>Mt Sinai J Med</i>. 1984; 51:215-7. http://www.ncbi.nlm.nih.gov/pubmed/6233486?dopt=AbstractPlus</p><p>65. Foster WM, Langenback EG, Glaser ML et al. Acute effect of ipratropium bromide at therapeutic dose on mucus transport of adult asthmatics. <i>Eur J Respir Dis</i>. 1983; 64(Suppl 128):554-7.</p><p>66. Francis RA, Thomson ML, Pavia D et al. Ipratropium bromide: mucociliary clearance rate and airway resistance in normal subjects. <i>Br J Dis Chest</i>. 1977; 71:173-8. http://www.ncbi.nlm.nih.gov/pubmed/142502?dopt=AbstractPlus</p><p>67. Pavia D, Bateman JRM, Sheahan NF et al. Effect of ipratropium bromide on mucociliary clearance and pulmonary function in reversible airways obstruction. <i>Thorax</i>. 1979; 34:501-7. http://www.ncbi.nlm.nih.gov/pubmed/159510?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=471105&amp;blobtype=pdf</p><p>68. Ruffin RE, Wolff RK, Dolovich MB et al. Aerosol therapy with Sch 1000: short-term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects. <i>Chest</i>. 1978; 73:501-6. http://www.ncbi.nlm.nih.gov/pubmed/344012?dopt=AbstractPlus</p><p>69. Wanner A. Effect of ipratropium bromide on airway mucociliary function. <i>Am J Med</i>. 1986; 81(Suppl 5A):23-7. http://www.ncbi.nlm.nih.gov/pubmed/2947458?dopt=AbstractPlus</p><p>70. Iravani J, Melville GN. Ciliary movement following various concentrations of different anticholinergic and adrenergic bronchodilator solutions in animals. <i>Postgrad Med J</i>. 1975; 51(Suppl 7) 108. Abstract No. 4/3.</p><p>71. Matthys H, Müller M, Konietzko N et al. Tracheobronchial clearance studies with and without Sch 1000 using<sup>99m</sup>technetium sulphate (<sup>99m</sup>Tc) particles. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):108.</p><p>72. Matthys H, Müller M, Konietzko N. Quantitative and selective bronchial clearance studies using<sup>99m</sup>Tc-sulfate particles. <i>Scand J Respir Dis</i>. 1974; 55(Suppl 85):33-45.</p><p>73. Foster WM, Bergofsky EH, Bohning DE et al. Effect of adrenergic agents and their mode of action on mucociliary clearance in man. <i>J Appl Physiol</i>. 1976; 41:146-52. http://www.ncbi.nlm.nih.gov/pubmed/956095?dopt=AbstractPlus</p><p>74. Pavia D, Thomson ML. Inhibition of mucociliary clearance from the human lung by hyoscine. <i>Lancet</i>. 1971; 1:449-50. http://www.ncbi.nlm.nih.gov/pubmed/4100417?dopt=AbstractPlus</p><p>75. Ghafouri MA, Patil KD, Kass I. Sputum changes associated with the use of ipratropium bromide. <i>Chest</i>. 1984; 86:387-93. http://www.ncbi.nlm.nih.gov/pubmed/6236043?dopt=AbstractPlus</p><p>76. Chervinsky P. Double-blind study of ipratropium bromide, a new anticholinergic bronchodilator. <i>J Allergy Clin Immunol</i>. 1977; 59:22-30. http://www.ncbi.nlm.nih.gov/pubmed/137921?dopt=AbstractPlus</p><p>77. Puchelle E, Uffholtz H. Sputum viscoelasticity following administration of Sch 1000 MDI. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):109.</p><p>78. Krieger E, Reitberger U. Sputum rheology following treatment with Sch 1000 MDI and orciprenaline MDI. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):108.</p><p>79. Stresemann E. Total airways resistance (R<sub>t</sub>), sputum volume and rheology in patients with chronic bronchitis following treatment with Sch 1000 MDI and placebo. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):110. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495722&amp;blobtype=pdf</p><p>80. May CS, Palmer KNV. Effect of aerosol ipratropium bromide (Sch 1000) on sputum viscosity and volume in chronic bronchitis. <i>Br J Clin Pharmacol</i>. 1977; 4:491-2. http://www.ncbi.nlm.nih.gov/pubmed/143293?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1429048&amp;blobtype=pdf</p><p>81. Coleman AJ, Leary UP, Kaul DS. Haemodynamic effects of Sch 1000 in normal subjects. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):121. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495922&amp;blobtype=pdf</p><p>82. Fabel H, Hartmann W, Wettengel R. Effects on central haemodynamics and blood gas tensions following increasing doses of inhaled Sch 1000 MDI in patients with chronic obstructive lung disease. <i>Postgrad Med</i>. 1975; 51(Suppl 7):121.</p><p>83. Grimaud C, Nicholi MM, Delpierre S et al. Action of Sch 1000 MDI on blood gas tensions and alveolar ventilation in patients with chronic obstructive airway disease (COAD). <i>Postgrad Med J</i>. 1975; 51(Suppl 7):121. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495922&amp;blobtype=pdf</p><p>84. Maesen FPV, Buytendijk HJ. Pulmonary haemodynamics and blood gas tensions in patients with chronic obstructive airways disease (COAD) following inhalation of a new parasympatholytic bronchodilator. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):123.</p><p>85. Marcq M, Minette A. Effects of Sch 1000 inhalation on arterial blood gases in patients with reversible airway obstruction. <i>Acta Tuberc Pneumol Belg</i>. 1975; 66:429-33. http://www.ncbi.nlm.nih.gov/pubmed/131480?dopt=AbstractPlus</p><p>86. Gross NJ, Petty TL, Friedman M et al. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. <i>Am Rev Respir Dis</i>. 1989; 139:188-91. http://www.ncbi.nlm.nih.gov/pubmed/2912339?dopt=AbstractPlus</p><p>87. Wieser 0, Königshofer R. Dose-response study of Sch 1000 MDI on heart rate, ECG and blood pressure in healthy volunteers. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):125. http://www.ncbi.nlm.nih.gov/pubmed/1219669?dopt=AbstractPlus</p><p>88. Wettengel R. The effects of Sch 1000 MDI in patients with mitral stenosis. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):125. http://www.ncbi.nlm.nih.gov/pubmed/1219669?dopt=AbstractPlus</p><p>89. Sill V, Voelkel N, Siemssen S et al. Effects of Sch 1000 MDI on the pulmonary circulation under hypoxic conditions. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):125. http://www.ncbi.nlm.nih.gov/pubmed/1219669?dopt=AbstractPlus</p><p>90. Brinkmann O. The results of long-term treatment with Sch 1000 MDI on repeated measurements of FEV<sub>10</sub>, total airways resistance (R<sub>t</sub>), haematological and biochemical tests in patients with chronic bronchitis and emphysema. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):130.</p><p>91. Haslreiter E. Haematological and biochemical monitoring during long-term treatment with Sch 1000 MDI in patients with chronic bronchitis and emphysema. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):130-1.</p><p>92. Jilg J. Long-term treatment with Sch 1000 MDI in outpatients with chronic bronchitis. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):131.</p><p>93. Chapman KR, Smith DL, Rebuck AS et al. Hemodynamic effects of inhaled ipratropium bromide, alone and combined with an inhaled beta<sub>2</sub>-agonist. <i>Am Rev Respir Dis</i>. 1985; 132:845-7. http://www.ncbi.nlm.nih.gov/pubmed/2864891?dopt=AbstractPlus</p><p>94. Bleichert A. The effects of atropine sulphate MDI and Sch 1000 MDI in low and very high dosages on salivation and pulse rate in healthy volunteers. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):112.</p><p>95. Sackner MA, Friedman M, Silva G et al. The pulmonary hemodynamic effects of aerosols of isoproterenol and ipratropium in normal subjects and patients with reversible airway obstruction. <i>Am Rev Respir Dis</i>. 1977; 116:1013-22. http://www.ncbi.nlm.nih.gov/pubmed/145195?dopt=AbstractPlus</p><p>96. Simonsson BG, Jonson B, Ström B. Bronchodilatory and circulatory effects of inhaling increasing doses of an anti-cholinergic drug, ipratropium bromide (SCH 1000). <i>Scand J Respir Dis</i>. 1975; 56:138-49. http://www.ncbi.nlm.nih.gov/pubmed/1162305?dopt=AbstractPlus</p><p>97. Kühns K, Stolte A. Controlled trial of Sch 1000 MDI in hypertensive patients as assessed by measurements of blood pressure and pulse rate at rest and during exercise. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):123.</p><p>98. Anderson WM. Hemodynamic and non-bronchial effects of ipratropium bromide. <i>Am J Med</i>. 1986; 81(Suppl 5A):45-53. http://www.ncbi.nlm.nih.gov/pubmed/2947460?dopt=AbstractPlus</p><p>99. Seider N, Abinader EG, Oliven A. Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. <i>Chest</i>. 1993; 104:1070-4. http://www.ncbi.nlm.nih.gov/pubmed/8404168?dopt=AbstractPlus</p><p>100. Dotevall G, Walan A. Long-term effect of ipratropium bromide on gastric secretion. <i>Arzneimittelforschung</i>. 1978; 28:2163-5. http://www.ncbi.nlm.nih.gov/pubmed/159057?dopt=AbstractPlus</p><p>101. Scherberger RR, Kaess H, Brückner S. Untersuchengen uber die Wirkung eines Anticholinergikums in Verbindung mit ein Tranquilizer auf die Magensaftsekretion beim Menschen. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1975; 25:1460-3.</p><p>102. Scheufler G. Ophthalmotonometry, pupil diameter and visual accommodation following repeated administration of Sch 1000 MDI in patients with glaucoma. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):132.</p><p>103. Thumm HW. Ophthalmic effects of high doses of Sch 1000 MDI in healthy volunteers and patients with glaucoma. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):132-3.</p><p>104. Molkenboer JFWM, Lardenoye JG. The effects of Atrovent in micturition function, double blind cross-over study. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):154-8.</p><p>105. Shenfield GM, Evans ME, Paterson JW. Absorption of drugs by the lung. <i>Br J Clin Pharmacol</i>. 1976; 3:583-9. http://www.ncbi.nlm.nih.gov/pubmed/22216498?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1428916&amp;blobtype=pdf</p><p>106. Adlung J, Höhle KD, Zeren S et al. Untersuchungen zur Pharmakokinetik und Biotransformation von Ipratropiumbromid am Menschen. (German; with English abstract). <i>Arzneimittelforschung</i>. 1976; 26:1005-10. http://www.ncbi.nlm.nih.gov/pubmed/134721?dopt=AbstractPlus</p><p>107. Rominger KL. Chemistry and pharmacokinetics of ipratropium bromide. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):116-29.</p><p>108. Davies DS. Pharmacokinetics of inhaled substances. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):44-9.</p><p>109. Wahl D. Pharmacokinetics (absorption-distribution-metabolism-excretion) of 14C- labelled Sch 1000 administered by inhalation, orally and intravenously. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):93-4.</p><p>110. Förster HJ, Kramer I, Pook KH et al. Untersuchungen zur Pharmakokinetik und Biotransformation von Ipratropiumbromid bei Ratte und Hund. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1976; 26:992-1005.</p><p>111. Loddenkemper R. Ipratropiumbromid, ein anticholinergischer Bronchodilatator: verhalten des Atemwegwiderstandes nach Inhalation verschiedener Dosierungen bei Patienten mit reversibler Atemwegobstruktion. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1976; 26:1017-20.</p><p>112. Ikeda A, Nishimura K, Koyama H et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD. <i>Chest</i>. 1995; 107:401-5. http://www.ncbi.nlm.nih.gov/pubmed/7842768?dopt=AbstractPlus</p><p>113. Massey KL, Gotz VP. Ipratropium bromide. <i>Drug Intell Clin Pharm</i>. 1985; 19:5-12. http://www.ncbi.nlm.nih.gov/pubmed/3155676?dopt=AbstractPlus</p><p>114. Lulling J, Delwiche JP, Ledent C et al. Controlled trial of the effect of repeated administration of ipratropium bromide on ventilatory function of patients with severe chronic airways obstruction. <i>Br J Dis Chest</i>. 1980; 74:135-41. http://www.ncbi.nlm.nih.gov/pubmed/6448618?dopt=AbstractPlus</p><p>115. Cockcroft DW, Cotton DJ, Berscheid BA. Long-term efficacy and safety of inhaled SCH 1000, an anticholinergic bronchodilator. <i>Curr Ther Res</i>. 1982; 31:138-47.</p><p>116. Cummiskey J, Keelan P. Study of Sch 1000 MDI used in therapeutic doses in patients with chronic bronchitis. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):130.</p><p>117. Minette A. Haematological and biochemical results during long-term treatment with Sch 1000. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):131.</p><p>118. Ulmer UT. Repeated measurements of total airways resistance (R<sub>t</sub>) intrathoracic gas volume (TGV), PaO<sup>2</sup>, PaCO<sup>2</sup> and clinical features in patients with chronic obstructive lung disease during long-term treatment with Sch 1000 inhalations. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):133.</p><p>119. Zeren S. Haematological and biochemical values in patients with chronic bronchitis and emphysema treated with Sch 1000 MDI over 3 months. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):133-4.</p><p>120. Tashkin DP, Ashutosh K, Bleecker ER et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. <i>Am J Med</i>. 1986; 81(Suppl 5A):81-90. http://www.ncbi.nlm.nih.gov/pubmed/2947465?dopt=AbstractPlus</p><p>121. Ashutosh K, Lang H. Comparison between long-term treatment of chronic bronchitic airway obstruction with ipratropium bromide and metaproterenol. <i>Ann Allergy</i>. 1984; 53:401-6. http://www.ncbi.nlm.nih.gov/pubmed/6238558?dopt=AbstractPlus</p><p>122. Krieger E. The effect of 2 different types of bronchodilators on FEV<sub>1-0</sub>, vital capacity (VC), and clinical features of airways obstruction in patients with chronic obstructive airways disease. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):115. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495719&amp;blobtype=pdf</p><p>123. Böhning W, Fabel H. Comparison of the onset of action of Sch 1000 and orciprenaline given by metered dose inhaler (MDI). <i>Postgrad Med J</i>. 1975; 51(Suppl 7):95.</p><p>124. Baigelman W, Chodosh S. Bronchodilator action of the anticholinergic drug, ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and asthma. <i>Chest</i>. 1977; 71:324-8. http://www.ncbi.nlm.nih.gov/pubmed/138578?dopt=AbstractPlus</p><p>125. Kummer F. The acute effect of an adrenergic and a parasympatholytic bronchodilator on obstructive lung disease as assessed by total airways resistance (Rt) in a double blind study. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):115. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495719&amp;blobtype=pdf</p><p>126. Douglas NJ, Davidson I, Sudlow MF et al. Bronchodilatation and the site of airway resistance in severe chronic bronchitis. <i>Thorax</i>. 1979; 34:51-6. http://www.ncbi.nlm.nih.gov/pubmed/155891?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=471007&amp;blobtype=pdf</p><p>127. Poppius H, Salorinne Y. Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis. <i>Br Med J</i>. 1973; 4:134-6. http://www.ncbi.nlm.nih.gov/pubmed/4584707?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1587144&amp;blobtype=pdf</p><p>128. Chapman TT. The effect of Sch 1000 MDI and salbutamol MDI on ventilatory function in patients with chronic bronchitis assessed by spirometry. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):112-3.</p><p>129. Petrie GR, Palmer KNV. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. <i>Br Med J</i>. 1975; 1:430-2. http://www.ncbi.nlm.nih.gov/pubmed/1090337?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1672418&amp;blobtype=pdf</p><p>130. Jenkins CR, Chow CM, Fisher BL et al. Comparison of ipratropium bromide and salbutamol by aerosolized sodium. <i>Aust N Z J Med</i>. 1981; 11:513-6. http://www.ncbi.nlm.nih.gov/pubmed/6459776?dopt=AbstractPlus</p><p>131. Maesen FPV. Comparison of the effects of Sch 1000 MDI and fenoterol MDI in patients with bronchial asthma and chronic bronchitis. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):116. http://www.ncbi.nlm.nih.gov/pubmed/1114147?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495703&amp;blobtype=pdf</p><p>132. Marlin GE, Bush DE, Berend N. Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis. <i>Br J Clin Pharmacol</i>. 1978; 6:547-9. http://www.ncbi.nlm.nih.gov/pubmed/153146?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1429707&amp;blobtype=pdf</p><p>133. Baronti A, Grieco A. A comparative trial of bronchodilator effects of fenoterol and SCH 1000 in chronic bronchitis. (Italian; with English abstract.) <i>Bull Eur Physiopathol Respir</i>. 1976; 12:533-43.</p><p>134. Minette A, Marcq M. Experience with Atrovent in coal miners. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):192-9.</p><p>135. Jaffé GV, Grimshaw JJ, Cox GA. A comparative trial of Atrovent and Ventolin in chronic bronchitis. <i>Practitioner</i>. 1980; 224:433-6. http://www.ncbi.nlm.nih.gov/pubmed/6448997?dopt=AbstractPlus</p><p>136. Addis GJ, Barclay J, Chang EM. Assessment of a combination of doses of fenoterol and ipratropium suitable for a single metered-dose aerosol. <i>Eur J Clin Pharmacol</i>. 1979; 16:97-100. http://www.ncbi.nlm.nih.gov/pubmed/159182?dopt=AbstractPlus</p><p>137. Longhini E, Bozzoni M, Mastropasqua B et al. Evaluation of the intensity and duration of the bronchodilatory action of fenoterol–ipratropium bromide in combination compared with terbutaline and placebo in patients with chronic obstructive lung disease. <i>Respiration</i>. 1986; 50(Suppl 2):169-72. http://www.ncbi.nlm.nih.gov/pubmed/2951799?dopt=AbstractPlus</p><p>138. Jenkins CR, Chow CM, Fisher BL et al. Ipratropium bromide and fenoterol by aerosolized solution. <i>Br J Clin Pharmacol</i>. 1982; 14:113-5. http://www.ncbi.nlm.nih.gov/pubmed/6213250?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1427571&amp;blobtype=pdf</p><p>139. Marangio E, Pesci A, Mori A et al. Clinical physiological data on the bronchodilator effect of Duovent versus salbutamol in chronic obstructive lung disease. <i>Respiration</i>. 1986; 50(Suppl 2):165-8. http://www.ncbi.nlm.nih.gov/pubmed/2951798?dopt=AbstractPlus</p><p>140. Macaluso S, Del Torre L. Efficacy and compliance to prolonged Duovent treatment of bronchospasm. <i>Respiration</i>. 1986; 50(Suppl 2):222-5. http://www.ncbi.nlm.nih.gov/pubmed/2951810?dopt=AbstractPlus</p><p>141. Cecere I, Funaro G, De Cataldis G et al. Long-term treatment with ’Duovent’ in elderly patients affected by chronic obstructive lung disease. <i>Respiration</i>. 1986; 50(Suppl 2):245-8. http://www.ncbi.nlm.nih.gov/pubmed/2951815?dopt=AbstractPlus</p><p>142. Aquilina R, Bergero F, Noceti P et al. Protective effect of Duovent versus salbutamol in long-term treatment. <i>Respiration</i>. 1986; 50(Suppl 2):240- 4. http://www.ncbi.nlm.nih.gov/pubmed/2951814?dopt=AbstractPlus</p><p>143. Petrie GR, Palmer KNV. Comparative trial of Sch 1000 MDI and salbutamol MDI in chronic bronchitis and bronchial asthma. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):117.</p><p>144. Guttersohn J, Joos H, Herzog H. The effect of R<sub>aw</sub> on Sch 1000 MDI or fenoterol MDI and the combined administration of subthreshold dosages of both compounds. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):113.</p><p>145. Kaik G. The effect on total airways resistance (R<sub>t</sub>) of adding Sch 1000 MDI to beta- adrenergics, and vice versa, in patients with chronic bronchitis and emphysema. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):114.</p><p>146. Marlin GE, Berend N, Harrison AC. Combined cholinergic antagonist and β<sub>2</sub>-adrenoceptor agonist bronchodilator therapy by inhalation. <i>Aust N Z J Med</i>. 1979; 9:511-4. http://www.ncbi.nlm.nih.gov/pubmed/161170?dopt=AbstractPlus</p><p>147. Sergysels R, Schandevyl SW, Yernault JC et al. The complementary effects of an anticholinergic and sympathicomimetic drug inhalation in patients with severe chronic obstructive lung disease. <i>Acta Tuberc Pneumol Belg</i>. 1976; 67:163-73. http://www.ncbi.nlm.nih.gov/pubmed/138353?dopt=AbstractPlus</p><p>148. Verstraeten JM. Bronchial response of asthmatic and bronchitic patients to fenoterol MDI with or without subsequent Sch 1000 MDI. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):120. http://www.ncbi.nlm.nih.gov/pubmed/1219668?dopt=AbstractPlus</p><p>149. Wildbolz U, Kyd K, Scherrer M. Ipratropium in addition to theophylline- sustained betastimulation. <i>Lung</i>. 1977; 154(2):141-2.</p><p>150. Casali L, Grassi C, Rampulla C et al. Clinical pharmacology of a combination of bronchodilators. <i>Int J Clin Pharmacol Biopharm</i>. 1979; 7:277-80.</p><p>151. Easton PA, Jadue C, Dhingra S et al. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. <i>N Engl J Med</i>. 1986; 315:735-9. http://www.ncbi.nlm.nih.gov/pubmed/2943994?dopt=AbstractPlus</p><p>152. Leitch AG, Hopkin JM, Ellis DA et al. The effect of aerosol ipratropium bromide and salbutamol on exercise and tolerance in chronic bronchitis. <i>Thorax</i>. 1978; 33:711-3. http://www.ncbi.nlm.nih.gov/pubmed/154748?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=470968&amp;blobtype=pdf</p><p>153. Lightbody IM, Ingram CG, Legge JS et al. Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis. <i>Br J Dis Chest</i>. 1978; 72:181-6. http://www.ncbi.nlm.nih.gov/pubmed/151547?dopt=AbstractPlus</p><p>154. Brown IG, Chan CS, Kelly CA et al. Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation. <i>Thorax</i>. 1984; 39:272-6. http://www.ncbi.nlm.nih.gov/pubmed/6232724?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=459782&amp;blobtype=pdf</p><p>155. Petrie GR, Palmer KNV. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. <i>Br Med J</i>. 1975; 1:430-2. http://www.ncbi.nlm.nih.gov/pubmed/1090337?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1672418&amp;blobtype=pdf</p><p>156. Baronti A, Grieco A, Lelli M et al. Comparison of bronchodilator effects of Duovent and reproterol in patients with chronic reversible airway obstruction. <i>Respiration</i>. 1986; 50(Suppl 2):173-6. http://www.ncbi.nlm.nih.gov/pubmed/2951800?dopt=AbstractPlus</p><p>157. Kreisman H, Frank H, Wolkove N et al. Anticholinergic therapy in bronchial asthma. Synergistic effect of ipratropium and theophylline. <i>Am Rev Respir Dis</i>. 1978; 117:142.</p><p>158. Lefcoe NM, Toogood JH, Blennerhassett G et al. The addition of an oral beta agonist plus theophylline in asthma and bronchitis. <i>Chest</i>. 1982; 82:300-5. http://www.ncbi.nlm.nih.gov/pubmed/6213382?dopt=AbstractPlus</p><p>159. Rasmussen FV, Madsen L, Bundgaard A. Combined effect of an anticholinergic drug ipratropium bromide and disodium cromoglycate in exercise induced asthma. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):159-62.</p><p>160. Ajewski Z, Popiak B. The relation between permanent administration of Atrovent and the dose of steroids in chronic bronchitis. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):205.</p><p>161. National Asthma Education Program, National Institutes of Health. Executive summary: guidelines for the diagnosis and management of asthma. US Department of Health and Human Services, Public Health Service, National Institutes of Health. Publication No.. 94-3042A. 1994 Jul.</p><p>162. Hockley B, Johnson NM. A comparison of three high doses of ipratropium bromide in chronic asthma. <i>Br J Dis Chest</i>. 1985; 79:379-84. http://www.ncbi.nlm.nih.gov/pubmed/2932138?dopt=AbstractPlus</p><p>163. Gross NJ. Sch 1000: a new anticholinergic bronchodilator. <i>Am Rev Respir Dis</i>. 1975; 112:823-8. http://www.ncbi.nlm.nih.gov/pubmed/128306?dopt=AbstractPlus</p><p>164. National Institutes of Health, National Heart, Lung, and Blood Institute. Global initiative for asthma: global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health. 1995 Jan:77-100. NIH/NHLBI Publication No. 95-3659.</p><p>165. Storms WW, DoPico GA, Reed CE. Aerosol Sch 1000: an anticholinergic bronchodilator. <i>Am Rev Respir Dis</i>. 1975; 111:419-22. http://www.ncbi.nlm.nih.gov/pubmed/123712?dopt=AbstractPlus</p><p>166. Yeager H Jr, Weinberg RM, Kaufman LV et al. Asthma: comparative bronchodilator effects of ipratropium bromide and isoproterenol. <i>J Clin Pharmacol</i>. 1978; 16:198-204.</p><p>167. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. <i>N Engl J Med</i>. 1994; 330:1362-7. http://www.ncbi.nlm.nih.gov/pubmed/8152449?dopt=AbstractPlus</p><p>168. Storms WW, Bodman SF, Nathan RA et al. Use of ipratropium bromide in asthma. <i>Am J Med</i>. 1986; 81(Suppl 5A):61-6. http://www.ncbi.nlm.nih.gov/pubmed/2947462?dopt=AbstractPlus</p><p>169. Ruffin RE, Fitzgerald JD, Rebuck AS. A comparison of the bronchodilator activity of Sch 1000 and salbutamol. <i>J Allergy Clin Immunol</i>. 1977; 59:136-41. http://www.ncbi.nlm.nih.gov/pubmed/137922?dopt=AbstractPlus</p><p>170. Laitinen LA, Poppius H, Haahtela T. Comparison of ipratropium bromide and salbutamol in a long-term trial in asthmatic and bronchitic patients in a cold climate. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):163-9.</p><p>171. Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. <i>Thorax</i>. 1981; 36:523-9. http://www.ncbi.nlm.nih.gov/pubmed/6458920?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1020435&amp;blobtype=pdf</p><p>172. Bell R, Sahay JN, Barber PV et al. A therapeutic comparison of ipratropium bromide and salbutamol in asthmatic patients. <i>Curr Med Res Opin</i>. 1982; 8:242-6. http://www.ncbi.nlm.nih.gov/pubmed/6217949?dopt=AbstractPlus</p><p>173. Hall SK. Acute angle-closure glaucoma as a complication of combined β-agonist and ipratropium bromide therapy in the emergency department. <i>Ann Emergency Med</i>. 1994; 23:884-7.</p><p>174. Leahy BC, Gomm SA, Allen SC. Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma. <i>Br J Dis Chest</i>. 1983; 77:159-63. http://www.ncbi.nlm.nih.gov/pubmed/6223651?dopt=AbstractPlus</p><p>175. Jindal SK, Malik SK. Clinical experience with terbutaline sulphate and ipratropium bromide in bronchial asthma. <i>Indian J Chest Dis Allied Sci</i>. 1979; 21:130-3. http://www.ncbi.nlm.nih.gov/pubmed/160398?dopt=AbstractPlus</p><p>176. Boehringer Ingelheim. Atrovent<sup></sup> (ipratropium bromide) inhalation solution prescribing information. In: Krogh CME, ed. Compendium of pharmaceuticals and specialties 1995. 30th ed. Ottawa, Ontario: Canadian Pharmaceutical Association; 1995:130-1.</p><p>177. Emirgil C, Dwyer K, Baskette P et al. A new parasympatholytic bronchodilator: a study of its onset of effect after inhalation. <i>Curr Ther Res</i>. 1975; 17:215-24. http://www.ncbi.nlm.nih.gov/pubmed/805016?dopt=AbstractPlus</p><p>178. Schlueter DP, Neumann JL. Double blind comparison of acute bronchial and ventilation-perfusion changes to Atrovent and isoproterenol. <i>Chest</i>. 1978; 73:982-3. http://www.ncbi.nlm.nih.gov/pubmed/150323?dopt=AbstractPlus</p><p>179. Vlagopoulos T, Townley R, Ghazanshahi S et al. Comparison of the onset of action and bronchodilation effects of the anticholinergic agent SCH 1000 with isoproterenol. <i>J Allergy Clin Immunol</i>. 1975; 55:99.</p><p>180. Ahonen A, Alanko K, Mattson K. Bronchodilator action of two different doses of ipratropium bromide (Sch 1000) compared with fenoterol and placebo. <i>Curr Ther Res</i>. 1978; 24:65-75.</p><p>181. Spector S, Ball E Jr. Bronchodilating effects of aerosolized Sch 1000 and atropine sulfate in asthmatics. <i>Chest</i>. 1975; 68:426.</p><p>182. Rebuck AS, Gent M, Chapman KR. Anticholinergic and sympathomimetic combination therapy of asthma. <i>J Allergy Clin Immunol</i>. 1983; 71:317-23. http://www.ncbi.nlm.nih.gov/pubmed/6219156?dopt=AbstractPlus</p><p>183. Flint KC, Hockley B. A comparison between a combination of ipratropium bromide plus fenoterol single metered dose inhaler (Duovent) and salbutamol in asthma. <i>Postgrad Med J</i>. 1983; 59:724-5. http://www.ncbi.nlm.nih.gov/pubmed/6227877?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2417671&amp;blobtype=pdf</p><p>184. Anderson G, Jariwalla AG, Turnbull P et al. The effects of fenoterol, ipratropium bromide and their combination in asthma and chronic bronchitis. <i>IRCS Med Sci</i>. 1981; 9:251.</p><p>185. Alanko K, Sahlström K, Härkonen R. Combination of fenoterol and ipratropium bromide in the treatment of bronchial asthma. <i>Eur J Respir Dis</i>. 1983; 64(Suppl 128):546-7.</p><p>186. Bruderman I, Cohen-Aronovski R, Smorzik J. A comparative study of various combinations of ipratropium bromide and metaproterenol in allergic asthmatic patients. <i>Chest</i>. 1983; 83:208-10. http://www.ncbi.nlm.nih.gov/pubmed/6217951?dopt=AbstractPlus</p><p>187. Kreisman H, Cohen C, Ghezzo H et al. Combined therapy with ipratropium and theophylline in asthma. <i>Ann Allergy</i>. 1984; 52:90-3. http://www.ncbi.nlm.nih.gov/pubmed/6230034?dopt=AbstractPlus</p><p>188. Bonsignore G, Bellia V, Peralta G et al. The combination of fenoterol and ipratropium bromide in bronchial asthma: comparison of the acute effects of two different dosages. <i>Respiriration</i>. 1986; 50(Suppl 2):148-51.</p><p>189. Frith PA, Ruffin RE, Cockcroft DW et al. A comparison of the protective effect of sch 1000 and fenoterol against bronchoconstriction induced by histamine and methacholine. <i>J Allergy Clin Immunol</i>. 1978; 61:175.</p><p>190. Boehringer Ingelheim, Ridgefield, CT: Personal communication.</p><p>191. Reviewers’ comments (personal observations).</p><p>192. Rebuck AS, Marcus HI. Sch 1000 in psychogenic asthma. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):186-91.</p><p>193. Schuh S, Johnson DW, Callahan S et al. Efficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthma. <i>J Pediatr</i>. 1995; 126:639-45. http://www.ncbi.nlm.nih.gov/pubmed/7699549?dopt=AbstractPlus</p><p>194. Desche P, Cournot A, Duchier J et al. Airway responses to salbutamol and to ipratropium bromide after non-selective and cardioselective beta-blocker. <i>Eur J Clin Pharmacol</i>. 1987; 32:343-6. http://www.ncbi.nlm.nih.gov/pubmed/2886341?dopt=AbstractPlus</p><p>195. Gross NJ, Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Comparison with a beta-adrenergic agent. <i>Am Rev Respir Dis</i>. 1987; 136:1091-4. http://www.ncbi.nlm.nih.gov/pubmed/3118746?dopt=AbstractPlus</p><p>196. Fine SR. Possible reactions to soya lecithin in aerosols. <i>J Allergy Clin Immunol</i>. 1991; 87:600. http://www.ncbi.nlm.nih.gov/pubmed/1825215?dopt=AbstractPlus</p><p>197. Canadian Thoracic Society Workshop Group. Guidelines for the assessment and management of chronic obstructive pulmonary disease. <i>CMAJ</i>. 1992; 147:420-8. http://www.ncbi.nlm.nih.gov/pubmed/1498754?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1336240&amp;blobtype=pdf</p><p>198. Kosche F, Stemmann EA. Peak flow measurements following Sch 1000 MDI in children with reversible airways obstruction. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):127.</p><p>199. Kunkel G, Rudolph R, Stock U. Dose-titration and long-term studies in asthmatic children. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):127.</p><p>200. Logvinoff-Poidatz M, Geubelle F. Effects of Sch 1000 MDI on the lung function in asthmatic children. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):127.</p><p>201. Pulejo R, Romano L, Noto M. Double-blind study with Duovent and placebo in 20 asthmatic children. <i>Respiration</i>. 1986; 50(Suppl 2):236-9. http://www.ncbi.nlm.nih.gov/pubmed/2951813?dopt=AbstractPlus</p><p>202. Bratteby LE, Foucard T, Lönnerholm G. Combined treatment with ipratropium bromide and beta-2-adrenoceptor agonists in childhood asthma. <i>Eur J Respir Dis</i>. 1986; 68:239-47. http://www.ncbi.nlm.nih.gov/pubmed/2874047?dopt=AbstractPlus</p><p>203. Groggins RC, Milner AD, Stokes GM. Bronchodilator effects of clemastine, ipratropium bromide, and salbutamol in preschool children with asthma. <i>Arch Dis Child</i>. 1981; 56:342-4. http://www.ncbi.nlm.nih.gov/pubmed/6455096?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1627441&amp;blobtype=pdf</p><p>204. Henry RL, Hiller EJ, Milner AD et al. Nebulised ipratropium bromide and sodium cromoglycate in the first two years of life. <i>Arch Dis Child</i>. 1984; 59:54-7. http://www.ncbi.nlm.nih.gov/pubmed/6230059?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1628434&amp;blobtype=pdf</p><p>205. Beck R, Robertson C, Galdès-Sebaldt M et al. Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. <i>J Ped</i>. 1985; 107:605-8.</p><p>206. Hofmann D, Wönne R. Action of Sch 1000 MDI and fenoterol on bronchial obstruction induced by allergen challenge. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):126.</p><p>207. Stemmann EA, Kosche F, Braun SH. The assessment of Sch 1000 MDI and/or beta-adrenergics in asthmatic children. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):128.</p><p>208. Lin MT, Lee-Hong E, Collins-Williams C. A clinical trial of the bronchodilator effect of Sch 1000 aerosol in asthmatic children. <i>Ann Allergy</i>. 1978; 40:326-32. http://www.ncbi.nlm.nih.gov/pubmed/347990?dopt=AbstractPlus</p><p>209. Turner M. Compatibility of nebuliser solutions. <i>Aust J Hosp Pharm</i>. 1987; 17:241-2.</p><p>210. Lahdensuo A, Viljanen AA, Muittari A. A comparative study on the effect of Sch 1000 MDI, salbutamol and placebo MDI in bronchial asthma. <i>Postgrad Med J</i>. 1975; 51(Suppl 7):116. http://www.ncbi.nlm.nih.gov/pubmed/1114147?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2495703&amp;blobtype=pdf</p><p>211. Rebuck AS, Chapman KR, Abboud P et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. <i>Am J Med</i>. 1987; 82:59-64.</p><p>212. Lichterfeld A. Safety of Atrovent. <i>Scand J Respir Dis</i>. 1979; 103(Suppl):143-6.</p><p>213. Connolly CK. Adverse reaction to ipratropium bromide. <i>BMJ</i>. 1982; 285:934-5. http://www.ncbi.nlm.nih.gov/pubmed/6214296?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1499978&amp;blobtype=pdf</p><p>214. Farrow PR, Fancourt GJ. Does ipratropium bromide by nebulizer and face-mask have local ocular effects? <i>Human Toxicol</i>. 1986; 5:53-4.</p><p>215. Iacono M, Johnson GJ, Bury RW. An investigation of the compatibility of ipratropium and sodium cromoglycate nebuliser solutions. <i>Aust J Hosp Pharm</i>. 1987; 17:158-60.</p><p>216. Nadel JA. Ipratropium bromide nebuliser therapy and airway submucosal gland secretion. <i>Lancet</i>. 1982; 2:823. http://www.ncbi.nlm.nih.gov/pubmed/6126694?dopt=AbstractPlus</p><p>217. Friberg S, Graff-Lonnevig V. Ipratropium bromide (Atrovent) in childhood asthma: a cumulative dose-response study. <i>Ann Allergy</i>. 1989; 62:131-4. http://www.ncbi.nlm.nih.gov/pubmed/2521989?dopt=AbstractPlus</p><p>218. Sarafana L, Clark GC, Stötzer H. Toxikologische untersuchungen mit ipratropiumbromid. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1976; 26:985-9.</p><p>219. Niggeschulze A, Palmer AK. Reproduktionstoxikologische untersuchungen mit ipratropiumbromid. (German; with English abstract.) <i>Arzneim-Forsch</i>. 1976; 26:989.</p><p>220. Kreisman H, Frank H, Wolkove N et al. Synergism between ipratropium and theophylline in asthma. <i>Thorax</i>. 1981; 36:387-91. http://www.ncbi.nlm.nih.gov/pubmed/6458919?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=471515&amp;blobtype=pdf</p><p>221. Allen CJ, Campbell AH. Dose response of ipratropium bromide assessed by two methods. <i>Thorax</i>. 1979; 34:137-9.</p><p>222. Reisman J, Galdes-Sebalt M, Kazim F et al. Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. <i>J Allergy Clin Immunol</i>. 1988; 81:16-20. http://www.ncbi.nlm.nih.gov/pubmed/2963059?dopt=AbstractPlus</p><p>223. DeStefano G, Bonetti S, Bonizzato C et al. Additive effect of albuterol and ipratropium bromide in the treatment of bronchospasm in children. <i>Ann Allergy</i>. 1990; 65:260-2. http://www.ncbi.nlm.nih.gov/pubmed/2145790?dopt=AbstractPlus</p><p>224. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 30th ed. London; The Pharmaceutical Press, 1992:427.</p><p>225. Gross NJ. Ipratropium bromide. <i>N Engl J Med</i>. 1988; 319:486-94. http://www.ncbi.nlm.nih.gov/pubmed/2970009?dopt=AbstractPlus</p><p>226. Howarth PH, Durham SR, Lee TH et al. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. <i>Am Rev Respir Dis</i>. 1985; 132:986-92. http://www.ncbi.nlm.nih.gov/pubmed/2932989?dopt=AbstractPlus</p><p>227. Ind PW, Dixon CMS, Fuller RW et al. Anticholinergic blockade of propranolol induced bronchoconstriction. <i>Thorax</i>. 1986; 41:718.</p><p>228. Mann KV, Leon AL, Tietze KJ. Use of ipratropium bromide in obstructive lung disease. <i>Clin Pharm</i>. 1988; 7:670-80. http://www.ncbi.nlm.nih.gov/pubmed/2977109?dopt=AbstractPlus</p><p>229. Ensing K, de Zeeuw RA, Nossent GD et al. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. <i>Eur J Clin Pharmacol</i>. 1989; 36:189-94. http://www.ncbi.nlm.nih.gov/pubmed/2524387?dopt=AbstractPlus</p><p>230. Anon. Ipratropium. <i>Med Lett Drugs Ther</i>. 1987; 29:71-2. http://www.ncbi.nlm.nih.gov/pubmed/2885730?dopt=AbstractPlus</p><p>231. Fisons. Tilade<sup></sup> (nedocromil sodium) inhalation aerosol patient information. (undated).</p><p>232. Lammers JWJ, Minette P, McCusker M et al. The role of pirenzepine-sensitive (M<sub>1</sub>) muscarinic receptors in vagally mediated bronchoconstriction in humans. <i>Am Rev Respir Dis</i>. 1989; 139:446-9. http://www.ncbi.nlm.nih.gov/pubmed/2521552?dopt=AbstractPlus</p><p>233. Wesseling G, Mostert R, Wouters EFM. A comparison of the effects of anticholinergic and β<sub>2</sub>-agonist and combination therapy on respiratory impedance in COPD. <i>Chest</i>. 1992; 101:166-73. http://www.ncbi.nlm.nih.gov/pubmed/1530836?dopt=AbstractPlus</p><p>234. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjects. <i>Chest</i>. 1989; 96:984-7. http://www.ncbi.nlm.nih.gov/pubmed/2805869?dopt=AbstractPlus</p><p>235. Magnussen H, Nowak D, Wiebicke W. Effect of inhaled ipratropium bromide on the airway response to methacholine, histamine, and exercise in patients with mild bronchial asthma. <i>Respiration</i>. 1992; 59:42-7. http://www.ncbi.nlm.nih.gov/pubmed/1533724?dopt=AbstractPlus</p><p>236. Peters MJ, Breslin ABX, Berend N. The effect of anticholinergic and beta-agonist pretreatment of bronchoconstriction induced by N-formyl-methionyl-leucyl-phenylalanine. <i>Eur Respir J</i>. 1989; 2:946-9. http://www.ncbi.nlm.nih.gov/pubmed/2532605?dopt=AbstractPlus</p><p>237. Polosa R, Phillips GD, Rajakulasingam K et al. The effect of inhaled ipratropium bromide alone and in combination with oral terfenadine on bronchoconstriction provoked by adenosine 5′-monophosphate and histamine in asthma. <i>J Allergy Clin Immunol</i>. 1991; 87:939-47. http://www.ncbi.nlm.nih.gov/pubmed/1673977?dopt=AbstractPlus</p><p>238. Crimi N, Palermo F, Oliveri R et al. Protective effects of inhaled ipratropium bromide on bronchoconstriction induced by adenosine and methacholine in asthma. <i>Eur Respir J</i>. 1992; 5:560-5. http://www.ncbi.nlm.nih.gov/pubmed/1535321?dopt=AbstractPlus</p><p>239. Georgopoulos D, Giulekas D, Ilonidis G et al. Effect of salbutamol, ipratropium bromide and cromolyn sodium on prostaglandin F<sub>2α</sub>-induced bronchospasm. <i>Chest</i>. 1989; 96:809-14. http://www.ncbi.nlm.nih.gov/pubmed/2529105?dopt=AbstractPlus</p><p>240. Crimi N, Palermo F, Oliveri R et al. Influence of antihistamine (astemizole) and anticholinergic drugs (ipratropium bromide) on bronchoconstriction induced by substance P. <i>Ann Allergy</i>. 1990; 65:115-20. http://www.ncbi.nlm.nih.gov/pubmed/1696438?dopt=AbstractPlus</p><p>241. McManus MS, Koenig JQ, Altman LC et al. Pulmonary effects of sulfur dioxide exposure and ipratropium bromide pretreatment in adults with nonallergic asthma. <i>J Allergy Clin Immunol</i>. 1989; 83:619-26. http://www.ncbi.nlm.nih.gov/pubmed/2522475?dopt=AbstractPlus</p><p>242. Watson WTA, Becker AB, Simons FER. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. <i>J Allergy Clin Immunol</i>. 1988; 82:1012-8. http://www.ncbi.nlm.nih.gov/pubmed/2974463?dopt=AbstractPlus</p><p>243. Quieffin J, Hunter J, Schechter MT et al. Aerosol pentamidine-induced bronchoconstriction: predictive factors and preventive therapy. <i>Chest</i>. 1991; 100:624-27. http://www.ncbi.nlm.nih.gov/pubmed/1832372?dopt=AbstractPlus</p><p>244. Gross NJ. The influence of anticholinergic agents on treatment for bronchitis and emphysema. <i>Am J Med</i>. 1991; 91(Suppl 4A):11-2S.</p><p>245. Karpel JP, Pesin J, Greenberg D et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. <i>Chest</i>. 1990; 98:835-9. http://www.ncbi.nlm.nih.gov/pubmed/2145136?dopt=AbstractPlus</p><p>246. Kalra L, Bone MF. The effect of nebulized bronchodilator therapy on intraocular pressures in patients with glaucoma. <i>Chest</i>. 1988; 93:739-41. http://www.ncbi.nlm.nih.gov/pubmed/2964995?dopt=AbstractPlus</p><p>247. D’Arcy PF. Glaucoma associated with nebulised ipratropium and salbutamol. <i>Int Pharm J</i>. 1992; 6:53.</p><p>248. Shah P, Dhurjon L, Metcalfe T et al. Acute angle closure glaucoma associated with nebulised ipratropium bromide and salbutamol. <i>BMJ</i>. 1992; 304:40-1. http://www.ncbi.nlm.nih.gov/pubmed/1531182?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1880919&amp;blobtype=pdf</p><p>249. Reuser T, Flanagan DW, Borland C et al. Acute angle closure glaucoma occurring after nebulized bronchodilator treatment with ipratropium bromide and salbutamol. <i>J R Soc Med</i>. 1992; 85:499-500. http://www.ncbi.nlm.nih.gov/pubmed/1404209?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1293605&amp;blobtype=pdf</p><p>250. Roberts TE, Pearson DJ. Wide eyed and breathless. <i>BMJ</i>. 1989; 299:1348. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1838165&amp;blobtype=pdf</p><p>251. Pras E, Stienlauf S, Pinkhas J et al. Urinary retention associated with ipratropium bromide. <i>DICP</i>. 1991; 25:939-40. http://www.ncbi.nlm.nih.gov/pubmed/1835224?dopt=AbstractPlus</p><p>252. Lozewicz S. Bladder outflow obstruction induced by ipratropium bromide. <i>Postgrad Med J</i>. 1989; 65:260-1. http://www.ncbi.nlm.nih.gov/pubmed/2480586?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2429273&amp;blobtype=pdf</p><p>253. Skorodin MS. Pharmacotherapy for asthma and chronic obstructive pulmonary disease. <i>Arch Intern Med</i>. 1993; 153:814-28. http://www.ncbi.nlm.nih.gov/pubmed/8096690?dopt=AbstractPlus</p><p>254. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. <i>N Engl J Med</i>. 1993; 328:1017-22. http://www.ncbi.nlm.nih.gov/pubmed/8450855?dopt=AbstractPlus</p><p>255. Listello D, Glauser F. COPD: primary care management with drug and oxygen therapies. <i>Geriatrics</i>. 1992; 47:28-38. http://www.ncbi.nlm.nih.gov/pubmed/1446842?dopt=AbstractPlus</p><p>256. Chapman KR. Therapeutic algorithm for chronic obstructive pulmonary disease. <i>Am J Med</i>. 1991; 91(Suppl 4A):17-23S.</p><p>257. Chapman KR. The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease. <i>Lung</i>. 1990; 168(Suppl):295-303. http://www.ncbi.nlm.nih.gov/pubmed/2143551?dopt=AbstractPlus</p><p>258. Braun SR, Levy SF, Grossman J. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. <i>Am J Med</i>. 1991; 91(Suppl 4A):28-32S.</p><p>259. Braun SR, McKenzie WN, Copeland C et al. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. <i>Arch Intern Med</i>. 1989; 149:544-7. http://www.ncbi.nlm.nih.gov/pubmed/2521997?dopt=AbstractPlus</p><p>260. Shrestha M, O’Brien T, Haddox R et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to β-agonist therapy. <i>Ann Emerg Med</i>. 1991; 20:1206-9. http://www.ncbi.nlm.nih.gov/pubmed/1835324?dopt=AbstractPlus</p><p>261. Nishimura K, Koyama H, Ikeda A et al. Is oral theophylline effective in combination with both inhaled anticholinergic agent and inhaled β<sub>2</sub>-agonist in the treatment of stable COPD? <i>Chest</i>. 1993; 104:179-84. (IDIS 317807)</p><p>262. LeDoux EJ, Morris JF, Temple WP et al. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. <i>Chest</i>. 1989; 95:1013-6. http://www.ncbi.nlm.nih.gov/pubmed/2523291?dopt=AbstractPlus</p><p>263. Karpel JP. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD. <i>Chest</i>. 1991; 99:871-6. http://www.ncbi.nlm.nih.gov/pubmed/1672634?dopt=AbstractPlus</p><p>264. Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. <i>Chest</i>. 1989; 95:861-4. http://www.ncbi.nlm.nih.gov/pubmed/2522385?dopt=AbstractPlus</p><p>265. Sanchez, I, Holbrow J et al. Acute bronchodilator response to a combination of beta- adrenergic and anticholinergic agents in patients with cystic fibrosis. <i>J Pediatr</i>. 1992; 120:486-8. http://www.ncbi.nlm.nih.gov/pubmed/1531677?dopt=AbstractPlus</p><p>266. Sanchez I, De Koster J, Holbrow J et al. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. <i>Chest</i>. 1993; 104:842-6. http://www.ncbi.nlm.nih.gov/pubmed/8365299?dopt=AbstractPlus</p><p>267. American Thoracic Society. ATS Statement: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i>. 1995;152(Suppl):S78-120.</p><p>268. Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. <i>Am J Respir Crit Care Med</i>. 1995;151:1296-1316.</p><p>269. O’Driscoll BR, Taylor R, Horsley MG et al. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. <i>Lancet</i>. 1989; 1:1418-20. http://www.ncbi.nlm.nih.gov/pubmed/2567431?dopt=AbstractPlus</p><p>270. Bryant DH, Rogers P. Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma. <i>Chest</i>. 1992; 102:742-7. http://www.ncbi.nlm.nih.gov/pubmed/1387604?dopt=AbstractPlus</p><p>271. O’Callaghan C, Milner AD, Swarbrick A. Paradoxical bronchoconstriction in wheezing infants after nebulised preservative free iso-osmolar ipratropium bromide. <i>BMJ</i>. 1989; 299:1433-4. http://www.ncbi.nlm.nih.gov/pubmed/2532940?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1838282&amp;blobtype=pdf</p><p>272. Van Bever HP, Desager KN. Paradoxical bronchoconstriction in wheezing infants after nebulised ipratropium bromide. <i>Br Med J</i>. 1990; 300:397-8.</p><p>273. Milner AD, O’Callaghan C. Paradoxical bronchoconstriction in wheezing infants after nebulised ipratropium bromide. <i>Br Med J</i>. 1990; 300:398.</p><p>274. Markus HS. Paralytic ileus associated with ipratropium. <i>Lancet</i>. 1990; 355:1224.</p><p>275. Tuohy PG. Ipratropium and the eye. <i>N Z Med J</i>. 1989; 102:386. http://www.ncbi.nlm.nih.gov/pubmed/2529459?dopt=AbstractPlus</p><p>276. O’Driscoll BR. Supraventricular tachycardia caused by nebulised ipratropium bromide. <i>Thorax</i>. 1989; 44:312. http://www.ncbi.nlm.nih.gov/pubmed/2527421?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=461809&amp;blobtype=pdf</p><p>277. Bone WD, Amundson DF. An unusual case of severe anaphylaxis due to ipratropium bromide inhalation. <i>Chest</i>. 1993; 103:981-2.</p><p>278. Levin DC, Little KS, Laughlin KR et al. Ipratropium bromide solution in COPD augments extent and duration of FEV<sup>1 increases achieved by albuterol up to 85 days</sup>. <i>Chest</i>. 1993; 104(Suppl):112S.</p><p>279. Karpel J, Kotch A, Zinney M et al. Comparison of ipratropium, theophylline plus B-agonist, and all three in patients with COPD. <i>Chest</i>. 1993; 104(Suppl):112S.</p><p>280. Mulherin D, FitzGerald MX. Meconium ileus equivalent in association with nebulised ipratropium bromide in cystic fibrosis. <i>Lancet</i>. 1990; 355:552.</p><p>281. Boehringer Ingelheim. Atrovent<sup></sup> (ipratropium bromide) inhalation solution product monograph. Ridgefield, CT; 1993 Nov.</p><p>282. Boehringer Ingelheim. Atrovent<sup></sup> (ipratropium bromide) inhalation solution product information. Ridgefield, CT; 1993 Dec.</p><p>283. Hampson NB, Mueller MP. Cooling of metered-dose inhalers decrease pressure output from canisters. <i>N Engl J Med</i>. 1989; 320:321. http://www.ncbi.nlm.nih.gov/pubmed/2563147?dopt=AbstractPlus</p><p>284. Lourenco RV, Cotromanes E. Clinical aerosols: I. characterization of aerosols and their diagnostic uses. <i>Arch Intern Med</i>. 1982; 142:2163-72. http://www.ncbi.nlm.nih.gov/pubmed/6753780?dopt=AbstractPlus</p><p>285. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. <i>Chest</i>. 1994; 105:1411-9. http://www.ncbi.nlm.nih.gov/pubmed/8181328?dopt=AbstractPlus</p><p>286. Watson WTA, Shuckett P, Becker AB et al. Effect of nebulized ipratropium bromide on intraocular pressure in children. <i>Chest</i>. 1994; 105:1439-41. http://www.ncbi.nlm.nih.gov/pubmed/8181333?dopt=AbstractPlus</p><p>287. Armstrong GP, Braatvedt GD. Nebulised bronchodilators and eye complications. <i>New Ethicals</i>. 1994; 31:41-2.</p><p>288. Packe GE, Cayton RM, Mashhoudi N. Nebulised ipratropium bromide and salbutamol causing closed-angle glaucoma. <i>Lancet</i>. 1984; 2:691. http://www.ncbi.nlm.nih.gov/pubmed/6147708?dopt=AbstractPlus</p><p>289. Malani JT, Robinson GM, Seneviratne EL. Ipratropium bromide induced angle closure glaucoma. <i>N Z Med J</i>. 1982; 95:749. http://www.ncbi.nlm.nih.gov/pubmed/6216428?dopt=AbstractPlus</p><p>290. Kil H, Rooke GA, Ryan-Dykes MA et al. Effect of prophylactic bronchodilator treatment on lung resistance after tracheal intubation. <i>Anesthesiology</i>. 1994; 81:43-8. http://www.ncbi.nlm.nih.gov/pubmed/8042809?dopt=AbstractPlus</p><p>291. Nisar M, Earis JE, Pearson MG et al. Acute bronchodilator trials in chronic obstructive pulmonary disease. <i>Am Rev Respir Dis</i>. 1992; 146:555-9. http://www.ncbi.nlm.nih.gov/pubmed/1387772?dopt=AbstractPlus</p><p>292. Jacobs M. Maintenance therapy for obstructive lung disease. <i>Postgrad Med</i>. 1994; 95:87-99.</p><p>293. Fromm RE Jr, Varon J. Acute exacerbations of obstructive lung disease. <i>Postgrad Med</i>. 1994; 95:101-6.</p><p>294. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV<sub>1</sub>. <i>JAMA</i>. 1994; 272:1497-505. http://www.ncbi.nlm.nih.gov/pubmed/7966841?dopt=AbstractPlus</p><p>295. Yang SC, Yang SP, Lee TS. Nebulized ipratropium bromide in ventilator-assisted patients with chronic bronchitis. <i>Chest</i>. 1994; 105:1511-5. http://www.ncbi.nlm.nih.gov/pubmed/8181345?dopt=AbstractPlus</p><p>296. Mulpeter KM, Walsh JB, O’Connor M et al. Ocular hazards of nebulized bronchodilators. <i>Postgrad Med J</i>. 1992; 68:132-3. http://www.ncbi.nlm.nih.gov/pubmed/1533281?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2399205&amp;blobtype=pdf</p><p>297. Diamond L, Dockhorn RJ, Grossman J et al. A dose-response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the the common cold. <i>J Allergy Clin Immunol</i>. 1995; 95:1139-46. http://www.ncbi.nlm.nih.gov/pubmed/7751531?dopt=AbstractPlus</p><p>298. Bronsky EA, Druce H, Findlay SR et al. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. <i>J Allergy Clin Immunol</i>. 1995; 95:1117-22. http://www.ncbi.nlm.nih.gov/pubmed/7751528?dopt=AbstractPlus</p><p>299. Inoue H, Aizawa H, Takata S et al. Ipratropium bromide protects against bronchoconstriction during bronchoscopy. <i>Lung</i>. 1994; 172:2930-8.</p><p>300. Lee H, Amon S, Silverman M. Bronchodilator aerosol adminstered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome. <i>Arch Dis Child</i>. 1994; 70:F218-22.</p><p>301. Brundage KL, Mohsini KG, Froese AB et al. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. <i>Am Rev Respir Dis</i>. 1990; 142:1137-42. http://www.ncbi.nlm.nih.gov/pubmed/2146910?dopt=AbstractPlus</p><p>302. Anon. Drugs for asthma. <i>Med Lett Drug Ther</i>. 1995; 37:1-4.</p><p>303. Goldstein RA, Paul WE, Metcalfe DD et al. Asthma. <i>Ann Intern Med</i>. 1994; 121:698-708. http://www.ncbi.nlm.nih.gov/pubmed/7944080?dopt=AbstractPlus</p><p>304. Wilkie RA, Bryan MH. Effect of bronchodilators on airway resistance in ventilation-dependent neonates with chronic lung disease. <i>J Pediatr</i>. 1987; 111:278-82. http://www.ncbi.nlm.nih.gov/pubmed/2956405?dopt=AbstractPlus</p><p>305. Karpel JP, Kotch A, Zinny M et al. A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. <i>Chest</i>. 1994; 105:1089-94. http://www.ncbi.nlm.nih.gov/pubmed/8162730?dopt=AbstractPlus</p><p>306. Lehrer PM, Hochron SM, Rausch L et al. Effects of aerosol ipratropium bromide on cardiac vagal tone. <i>Chest</i>. 1994; 105:1701-4. http://www.ncbi.nlm.nih.gov/pubmed/8205863?dopt=AbstractPlus</p><p>307. Eedy DJ, Bartan K, Stanford CF. Ipratropium bromide/terbutaline. <i>Postgrad Med J</i>. 1988; 64:306-7. http://www.ncbi.nlm.nih.gov/pubmed/2973007?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2428521&amp;blobtype=pdf</p><p>308. Liggett SB, Daughaday CC, Senior RM. Ipratropium in patients with COPD receiving cholinesterase inhibitors. <i>Chest</i>. 1988; 94:210-2. http://www.ncbi.nlm.nih.gov/pubmed/2968227?dopt=AbstractPlus</p><p>309. Ashutosh K, Dev G, Steele D. Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease. <i>Chest</i>. 1995; 107:173-8. http://www.ncbi.nlm.nih.gov/pubmed/7813271?dopt=AbstractPlus</p><p>310. Patel KR, Tullett WM. Bronchoconstriction in response to ipratropium bromide. <i>BMJ</i>. 1983; 286:1318. http://www.ncbi.nlm.nih.gov/pubmed/6220756?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1547644&amp;blobtype=pdf</p><p>311. Jolobe OMP. Adverse reaction to ipratropium bromide. <i>BMJ</i>. 1982; 285:1425-6.</p><p>312. Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel, long-acting beta 2-agonist. <i>Ann Pharmacother</i>. 1993; 27:1478-87. http://www.ncbi.nlm.nih.gov/pubmed/7905757?dopt=AbstractPlus</p><p>313. Kelly HW. Issues and advances in the pharmacotherapy of asthma. <i>J Clin Pharm Ther</i>. 1992; 17:271-81. http://www.ncbi.nlm.nih.gov/pubmed/1361192?dopt=AbstractPlus</p><p>314. British Thoracic Society. Guidelines on the management of asthma. <i>Thorax</i>. 1993; 48(Suppl 2):S1-24.</p><p>315. Svedmyr N. Action of corticosteroids on beta-adrenergic receptors: clinical aspects. <i>Am Rev Respir Dis</i>. 1990; 141:S31-8.</p><p>316. Anon. Salmeterol. <i>Med Lett Drugs Ther</i>. 1994; 36:37-9. http://www.ncbi.nlm.nih.gov/pubmed/7909139?dopt=AbstractPlus</p><p>317. Johnson ME. A multicentre study to compare the efficacy and safety of salmeterol xinofoate and nedocromil sodium via metered-dose inhalers in adults with mild-to-moderate asthma. <i>Eur J Clin Res</i>. 1994; 5:75-85.</p><p>318. O’Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. <i>N Engl J Med</i>. 1992; 327:1204-8. http://www.ncbi.nlm.nih.gov/pubmed/1357551?dopt=AbstractPlus</p><p>319. Reviewers’ comments (personal observations) on salmeterol 12:12.</p><p>320. Boehringer Ingelheim Pharmaceuticals. Combivent<sup></sup> (ipratropium bromide and albuterol sulfate) inhalation aerosol prescribing information.Ridgefield, CT; 2001 Sep.</p><p>321. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone; an 85-day multicenter trial. <i>Chest</i>. 1994; 105: 1411-9.</p><p>322. Key Pharmaceuticals. Proventil HFA<sup></sup> (albuterol sulfate) inhalation aerosol for oral inhalation prescribing information. Kenilworth, NJ; 1996 Aug. (reference 181 from albuterol)</p><p>323. Siafakas NM, Vermeire P, Pride NB et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). <i>Eur Respir J</i>. 1995: 8; 1398-420.</p><p>324. National Asthma Education and Prevention Program. Expert panel report II: guidelines for the diagnosis and management of asthma. 1997 Feb.</p><p>325. Boehringer Ingelheim Pharmaceuticals. Atrovent<sup></sup> (ipratropium bromide) Nasal Spray 0.03% prescribing information. In: Physicians’ desk reference. 54th ed. Montvale, NJ: Mecial Economics Company. 2000:791-2.</p><p>326. Boehringer Ingelheim Pharmaceuticals. Atrovent<sup></sup> (ipratropium bromide) Nasal Spray 0.06% prescribing information. In: Physicians’ desk reference. 54th ed. Montvale, NJ: Medical Economics Company. 2000:792-4.</p><p>327. Dey Laboratories. DuoNeb<sup></sup> (ipratropium bromide/albuterol sulfate) inhalation solution prescribing information. Napa, CA; 2005 Apr.</p><p>328. Dey. DuoNeb<sup></sup> (albuterol sulfate/ipratropium bromide) inhalation solution patient instructions. Napa, CA: 2005 Apr.</p><p>329. Dey. Ipratropium bromide 0.02% inhalation solution prescribing instructions. Napa, CA: 1998 Apr.</p><p>330. Dey,L.P. Napa, CA: Personal communication.</p><p>331. National Institutes of Health, National Heart, Lung, and Blood Institute. Global Initiative for asthma: global strategy for asthma management and prevention NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health. 2002 Feb. NIH/NHLBI Publication No. 02-3659. Available at: http://www.ginasthma.com. Accessed Sep. 26, 2002</p><p>332. National Heart, Lung, and Blood Institute/World Health Organization. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: National Heart, Lung, and Blood Institute, Global Initiative for Chronic Obstructive Lung Disease, World Health Organization; 2001. Available at: http://www.goldcopd.com/workshop/index.html. Accessed Sep. 26, 2002.</p><p>333. Veterans’ Health Administration Department of Veteran Affairs. The pharmacologic management of chronic obstructive pulmonary disease. Washington, DC: Veterans’ Health Administration; 1999 June. Pharmacy Benefits Management No. 99-0012. Available at https://www.pbm.va.gov. Accessed Sep. 30, 2002.</p><p>334. Veterans’ Health Administration, Department of Veterans’ Affairs. VHA/DOD clinical practice guideline for the management of chronic obstructive pulmonary disease: complete summary. Washington, DC: Veterans’ Health Administration; 1999 Aug.</p><p>335. Snow V, Lascher S, Mottur-Pilson C for the Joint Expert Panel of Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Clinical Practice Guideline, pt.1. <i>Ann Intern Med</i>. 2001; 134:595-9. http://www.ncbi.nlm.nih.gov/pubmed/11281744?dopt=AbstractPlus</p><p>336. National Institutes of Health, National Heart, Lung, and Blood Institute. Global initiative for asthma: global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Bethesda, MD: National Institutes of Health. 2003 Nov 21. NIH/NHLBI Publication No. 02-3659 (updated 2004). Available at: http://www.ginasthma.com. Accessed Sep 22, 2004.</p><p>337. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma. Update on selected topics 2002. Bethesda, Md: National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Coordinating Committee; 2003 Jun. Available from National Heart, Lung, and Blood Institute Information Center, NIH Publication No. 02-5074. Also available at https://www.nhlbi.nih.gov/. Accessed 2004 Sep. 15.</p><p>338. Boehringer Ingelheim. Spiriva<sup></sup> HandiHaler<sup></sup> (tiotropium bromide) inhalation powder prescribing information. Ridgefield, CT; 2004 Jan.</p><p>339. Vincken W, van Noord JA, Greefhirst APM et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. <i>Eur Respir J</i></p><p>340. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructuve pulmonary disease. <i>Eur Respir J</i>. 2002; 19:217-24. http://www.ncbi.nlm.nih.gov/pubmed/11866001?dopt=AbstractPlus</p><p>341. Anon. Tiotropium (Spiriva) for COPD. <i>Med Lett Drugs Ther</i>. 2004: 46:41-2.</p><p>342. Hvizdos KM, Goa KL. Tiotropium bromide. <i>Drugs</i>. 2002; 62:1195-203. http://www.ncbi.nlm.nih.gov/pubmed/12010082?dopt=AbstractPlus</p><p>343. ATS/ERS Standards for the diagnosis and management of patients with COPD. New York, NY: American Thoracic Society, European Respiratory Society; 2004. Available from website. Accessed Dec. 8, 2004. http://www.thoracic.org/clinical/copd-guidelines</p><p>344. O’Donnell DE, Aaron S, Bourbeau J et al. State of the art compendium: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. <i>Can Respir J</i>. 2004; 11 (Suppl. B):7B-59B.</p><p>345. Celli BR, Macnee W. Standard for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. <i>Eur Respir J</i>. 2004; 23:932-46. http://www.ncbi.nlm.nih.gov/pubmed/15219010?dopt=AbstractPlus</p><p>346. Boehringer Ingleheim. Combivent<sup></sup> (albuterol sulfate/ipratropium bromide) inhalation aerosol patient instructions for use. Ridgefield, CT: 2001 Sep.</p><p>347. National Heart, Lung, and Blood Institute/World Health Organization. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: National Heart, Lung, and Blood Institute, Global Initiative for Chronic Obstructive Lung Disease, World Health Organization; 2005 Sep. Available at: http://www.goldcopd.com. Accessed Oct. 5, 2005.</p><p>348. Boehringer Ingleheim. Atrovent<sup></sup> (ipratropium bromide) inhalation aerosol patient instructions for use. Ridgefield, CT: 2002 Mar. 27.</p><p>349. Dey. Ipratropium bromide inhalation solution 0.02% patient instructions. Napa, CA: 1998 Apr.</p><p>350. Boehringer Ingelheim. Atrovent<sup></sup> (ipratropium bromide) 0.02% inhalation solution patient instructions. Ridgefield, CT; 1998 Oct.</p><h2>More about ipratropium</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>14 Reviews</li>
<li>Drug class: anticholinergic bronchodilators</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ipratropium Inhalation, oral/nebulization &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Ipratropium &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>COPD, Maintenance</li>
<li>Asthma</li>
<li>Bronchiectasis</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>